| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161440213P | 2011-02-07 | 2011-02-07 | |
| US61/440,213 | 2011-02-07 |
| Publication Number | Publication Date |
|---|---|
| WO2012109233A2 WO2012109233A2 (en) | 2012-08-16 |
| WO2012109233A3true WO2012109233A3 (en) | 2012-10-04 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2012/024133WO2012109233A2 (en) | 2011-02-07 | 2012-02-07 | Methods for predicting recurrence risk in breast cancer patients |
| Country | Link |
|---|---|
| WO (1) | WO2012109233A2 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK177532B1 (en) | 2009-09-17 | 2013-09-08 | Bio Bedst Aps | Medical use of sPLA2 hydrolysable liposomes |
| CA2800557A1 (en) | 2010-04-29 | 2011-11-03 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy |
| WO2014195032A1 (en)* | 2013-06-07 | 2014-12-11 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients |
| WO2016046640A2 (en) | 2014-09-26 | 2016-03-31 | Medical Prognosis Institute A/S | Methods for predicting drug responsiveness |
| US9725769B1 (en) | 2016-10-07 | 2017-08-08 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
| AU2017258901A1 (en) | 2016-12-30 | 2018-07-19 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness in cancer patients |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080108091A1 (en)* | 2006-08-07 | 2008-05-08 | Hennessy Bryan T | Proteomic Patterns of Cancer Prognostic and Predictive Signatures |
| US7569345B2 (en)* | 2003-01-15 | 2009-08-04 | Genomic Health, Inc. | Gene expression markers for breast cancer prognosis |
| US20100209920A1 (en)* | 2002-03-13 | 2010-08-19 | Baker Joffre B | Gene Expression Profiling in Biopsied Tumor Tissues |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100209920A1 (en)* | 2002-03-13 | 2010-08-19 | Baker Joffre B | Gene Expression Profiling in Biopsied Tumor Tissues |
| US7569345B2 (en)* | 2003-01-15 | 2009-08-04 | Genomic Health, Inc. | Gene expression markers for breast cancer prognosis |
| US20080108091A1 (en)* | 2006-08-07 | 2008-05-08 | Hennessy Bryan T | Proteomic Patterns of Cancer Prognostic and Predictive Signatures |
| Title |
|---|
| AHMAD ET AL.: "Stromelysin 3: an independent prognostic factor for relapse-free survival in node- positive breast cancer and demonstration of novel breast carcinoma cell expression", AM. J. PATHOL., vol. 152, no. 3, March 1998 (1998-03-01), pages 721 - 728* |
| STANWAY ET AL.: "Steroid sulfatase: a new target for the endocrine therapy of breast cancer", ONCOLOGIST, vol. 12, no. 4, April 2007 (2007-04-01), pages 370 - 374* |
| Publication number | Publication date |
|---|---|
| WO2012109233A2 (en) | 2012-08-16 |
| Publication | Publication Date | Title |
|---|---|---|
| EP3208615A3 (en) | Uses of labeled hsp90 inhibitors | |
| CY1124307T1 (en) | PHARMACEUTICAL COMPOSITION, METHODS OF THERAPY AND USES THEREOF | |
| PH12016501728A1 (en) | Anti-angiogenesis therapy for the treatment of ovarian cancer | |
| MX2021010672A (en) | Diagnosis and therapy of cancer involving cancer stem cells. | |
| MX2014005800A (en) | Human notch receptor mutations and their use. | |
| MX366130B (en) | Bivalent inhibitors of iap proteins and therapeutic methods using the same. | |
| MX353482B (en) | METHODS FOR THE TREATMENT OF CANCER and INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR. | |
| BR112012020373A8 (en) | isolated antibody, cell, isolated nucleic acid, method of identification, cell proliferation inhibition, therapeutic treatment, determination of the presence of a tat419 protein, diagnosis of the presence of cancer and distribution of cytotoxic agent | |
| WO2012006589A3 (en) | Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling | |
| WO2012038068A8 (en) | Means and methods for the prediction of treatment response of a cancer patient | |
| MX2017014338A (en) | Targeted selection of patients for treatment with cortistatin derivatives. | |
| BR112013011480A2 (en) | cancer treatment method, method of enhancing the therapeutic effectiveness of an anticancer drug, pmo1183 or a pharmaceutically acceptable salt thereof, use thereof and kit for use in cancer treatment | |
| MX358517B (en) | Methods for determining drug efficacy using cereblon-associated proteins. | |
| WO2012177595A9 (en) | Compositions and methods for the therapy and diagnosis of cancer | |
| MX2013000675A (en) | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy. | |
| IN2015DN00450A (en) | ||
| WO2012109233A3 (en) | Methods for predicting recurrence risk in breast cancer patients | |
| SG11201400919RA (en) | Patient stratification and determining clinical outcome for cancer patients | |
| WO2012145535A3 (en) | Animal model of human cancer and methods of use | |
| WO2012170513A3 (en) | He4 based therapy for malignant disease | |
| IN2014MN01945A (en) | ||
| WO2012109466A3 (en) | Long non-coding rna spry4-it1 as a diagnostic and therapeutic agent | |
| WO2013093115A3 (en) | Marker sequences for breast cancer and the use thereof | |
| SG11202103913WA (en) | Method for quantifying molecular activity in cancer cells of a human tumour | |
| IN2014MN01944A (en) |
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | Ref document number:12744652 Country of ref document:EP Kind code of ref document:A2 | |
| NENP | Non-entry into the national phase | Ref country code:DE | |
| 122 | Ep: pct application non-entry in european phase | Ref document number:12744652 Country of ref document:EP Kind code of ref document:A2 |